O
Omeros Corporation (OMER)
NGM – Real Time Price. Currency in USD
14.76
+0.40 (2.79%)
At close: May 12, 2026, 4:00 PM EDT
14.85
+0.09 (0.61%)
After-hours: May 12, 2026, 7:42 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
14.76
+0.40 (2.79%)
At close: May 12, 2026, 4:00 PM EDT
14.85
+0.09 (0.61%)
After-hours: May 12, 2026, 7:42 PM EDT
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
| Name | Position |
|---|---|
| Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems |
| Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science |
| Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & President |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder |
| Mr. David J. Borges | VP of Finance, Chief Accounting Officer & Treasurer |
| Mr. David W. Ghesquiere |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | DEF 14A | e26114_omer-def14a.htm |
| 2026-03-31 | 8-K | omer20251116_8k.htm |
| 2026-03-31 | 10-K | omer20251231_10k.htm |
| 2026-01-07 | 8-K | omer20260107_8k.htm |
| 2025-12-29 | 8-K | omer20251218_8k.htm |
| 2025-12-01 | 8-K | omer20251024_8k.htm |
| 2025-11-13 | 8-K | omer20250825_8k.htm |
| 2025-10-15 | 8-K | omer20251014_8k.htm |
| 2025-08-14 | 8-K | omer20250521_8k.htm |
| 2025-08-14 | 10-Q | omer20250630_10q.htm |
| VP & Chief Business Development Officer |
| Mr. Peter B. Cancelmo J.D. | VP, General Counsel & Corporate Secretary |
| Mr. Peter W. Williams | Vice President of Human Resources |